Vaginal HRT that helps moisturise your vagina.

Imvaggis is a vaginal HRT that treats symptoms like vaginal dryness. When your oestrogen levels decrease during menopause, your vagina can feel irritated, dry and painful.
And that’s where vaginal oestrogen like Imvaggis comes in. To order Imvaggis, simply answer a few questions online, and we’ll recommend personalised treatments just for you.
Imvaggis is a treatment for vaginal symptoms of menopause, such as dryness and irritation. It works locally to increase oestrogen levels in your vagina. Vaginal dryness can affect both menopausal and non-menopausal women, but it’s most commonly seen during and after menopause. This is because it’s usually caused by decreased oestrogen levels, which happens during menopause, but other factors like dehydration, lack of blood flow to the vaginal walls, and stress also contribute to it.
Vaginal dryness is mainly treated using hormonal treatments. However, hormonal medication is only a temporary fix. Once you stop using it, your symptoms will return unless your body starts to produce more oestrogen.
Imvaggis contains estriol, a synthetic version of oestrogen. It's ‘bioidentical’ to the oestrogen naturally produced by your body. Bioidentical hormones have proven to be more effective than non-bioidentical ones.
Vaginal dryness is often caused by an oestrogen deficiency. So by increasing the amount of oestrogen in your vagina, Imvaggis can help moisten it, maintain its lining and retain its elasticity. It can also help prevent infection by restoring and maintaining vaginal pH, which helps to reduce bacterial growth and urinary tract infections.
There’s only a 0.03mg dose of Imvaggis available. It's used daily for three weeks, followed by twice a week till the end of the treatment course.
How we source info.
When we present you with stats, data, opinion or a consensus, we’ll tell you where this came from. And we’ll only present data as clinically reliable if it’s come from a reputable source, such as a state or government-funded health body, a peer-reviewed medical journal, or a recognised analytics or data body. Read more in our editorial policy.
Imvaggis contains the hormone estriol, which is administered through a dissolvable pessary inserted into your vagina. To use Imvaggis, follow the instructions below:
Repeat the steps daily, preferably in the evening before bedtime, for three weeks. After three weeks, insert one pessary twice a week.
Imvaggis starts to work within a couple of hours, but it’ll probably take a few weeks to months to see the full effects. It's important to keep using it, even if your symptoms improve. Usually symptoms come back once you stop using hormonal treatment, to help with this, your clinician may gradually reduce the dosage for you.
If you accidentally use too many pessaries, don't panic. While you may experience vaginal bleeding for a few days or feel sick, it won't cause any serious health complications. However, it's best to still phone a doctor for advice.
If you forget to use Imvaggis during the first three weeks (during daily use), skip the missed dose. Don’t use a double dose to make up for a missed one. But if you miss a dose after three weeks (when it’s used bi-weekly), use it another day instead.
How we source info.
When we present you with stats, data, opinion or a consensus, we’ll tell you where this came from. And we’ll only present data as clinically reliable if it’s come from a reputable source, such as a state or government-funded health body, a peer-reviewed medical journal, or a recognised analytics or data body. Read more in our editorial policy.
Have something specific you want to know? Search our info below, or ask our experts a question if you can’t find what you’re looking for.
Vaginal dryness: Individualised patient profiles, risks and mitigating measures. The EPMA Journal, 10(1), 73-79.
Patient education: Vaginal dryness (Beyond the Basics). UpToDate.
Effectiveness of Compounded Bioidentical Hormone Replacement Therapy: An Observational Cohort Study. BMC Women's Health 11, 27.
Current treatment options for postmenopausal vaginal atrophy. International Journal of Women's Health, 10, 387-395.
Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: A phase II, randomized, double-blind, placebo-controlled trial. 27(5), 526-534.
Registered with GMC (No. 4624794)
Meet DanielRegistered with GPhC (No. 2202465)
Meet SanjedaRegistered with GPhC (No. 2070724)
Meet CraigWe know health, but you know you.
Our experts tell you what’s safe, but you decide what’s best.
Answer a few questions and tell us about yourself. Get tailored advice from our clinicians so you can choose better.
Choose your treatment and how often you have it delivered.
We know things change. It’s the nature of life. We’ll check in regularly to make sure your treatment is still right for you.
Pause. Change. Skip. Start again. Any time you like.
Treated is fab wouldnt go anywhere else for medical issues
Simple. Easy. Professional
On time
Good
Pleased with the service, very straightforward to order and delivery was very fast.
Everything was quick and professional
We're making healthcare more about you. Sign up to our newsletter for personalised health articles that make a difference.
Disclaimer: The information provided on this page is not a substitute for professional medical advice, diagnosis, or treatment. If you have any questions or concerns about your health, please talk to a doctor.
We couldn't find what you're looking for.
Here's everything we treat. Or, if you're looking for something we don't have yet, you can suggest something.
If there’s a particular treatment or condition you’re looking for, tell us and we’ll look into it for you.
Submit your question here, or tell us if you’ve found an issue on our site.
We’ll get back to you very soon. We aim to respond to all queries in one working day.
You’re signed up to our newsletter. Keep an eye on your inbox for our latest update.
By clicking 'Subscribe now' you're agreeing to our Privacy Policy.
We’ve sent you an email asking you to confirm your email address.